HCW Biologics Inc. (HCWB): Price and Financial Metrics
GET POWR RATINGS... FREE!
HCWB Stock Price Chart Interactive Chart >
HCWB Price/Volume Stats
| Current price | $2.06 | 52-week high | $7.78 |
| Prev. close | $2.03 | 52-week low | $1.89 |
| Day low | $1.91 | Volume | 11,800 |
| Day high | $2.40 | Avg. volume | 54,379 |
| 50-day MA | $2.41 | Dividend yield | N/A |
| 200-day MA | $2.76 | Market Cap | 73.74M |
HCW Biologics Inc. (HCWB) Company Bio
HCW Biologics Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation and age-related diseases. The company is involved in developing HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. It is also developing HCW9218 as an injectable immunotherapeutic for patients with pancreatic, breast, ovarian, colorectal, and prostate cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Latest HCWB News From Around the Web
Below are the latest news stories about HCW Biologics Inc that investors may wish to consider to help them evaluate HCWB as an investment opportunity.
Masonic Cancer Center To Evaluate HCW Biologics'' Bifunctional Fusion Protein In Advanced CancersThe FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc''s (NASDAQ: HCWB ) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex Full story available on Benzinga.com |
Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced CancersThe FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex designed to drive anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities. Hing C. Wong, Ph |
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion ProteinUM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancersMIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that the Masonic Cancer Center, University of Min |
HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of ChemoHCW Biologics Inc (NASDAQ: HCWB ) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced Full story available on Benzinga.com |
Aptorum, HCW Biologics lead healthcare gainers; Star Equity, G Medical among losersAptorum APM +35%. HCW Biologics (HCWB) +18%. Star Equity STRR -30%. G Medical Innovations GMVD -21%. |
HCWB Price Returns
| 1-mo | -12.71% |
| 3-mo | -7.21% |
| 6-mo | -28.72% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -11.21% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...